John Kuttesch, PhD, MD

John Kuttesch, PhD, MD

Faculty Titles
Professor & Chief
Department of Pediatrics
Division of Pediatric Oncology

Cancer Specialty
Pediatric Oncology

Multidisciplinary Team
Neurological Cancers, Pediatric Cancers

Research Program
Cancer Therapeutics: Technology, Discovery and Targeted Delivery

NIH Biosketch
View Biosketch

Medical School
University of Texas-Houston Health Sciences Center (June 1985)

Internship
Vanderbilt University Medical Center (June 1986)

Residency
Vanderbilt University Medical Center (June 1988)
Pediatrics

Fellowship
St. Jude Children’s Research Hospital (Jun 1990) Pediatric Hematology/Oncology and Pediatric Neuro-Oncology

Board Certification
American Board of Pediatrics,1989, Recertifications 2000 and 2006
American Board of Pediatric Hematology-Oncology 1992, Recertifications 1998 and 2006

Expertise, Certifications and Memberships
Pediatric Solid Tumors, Neuro-Oncology, Early Phase Clinical Trials

Personal Statement

My primary role at the University of New Mexico is Division Chief of Pediatric Hematology/Oncology, since November, 2012.

My research interests are clinical trial development and implementation. I have experience in Phase I and II investigational agent trials focusing on childhood brain tumors

My role in this project proposal is Director of Pediatric Oncology, UNM Comprehensive Cancer Center and head of the Pediatric Clinical Working group. I am the current PI for the Children’s Oncology Group (COG) contract at the University of New Mexico. In this role, I manage the COG budgets, the conduct of COG trials, oversee enrollment, as well as supervise the team of 3 clinical research coordinators.

I have previous served as PI for COG at the Penn State University as well as at Vanderbilt University. I also have extensive experience in the development and management of Early Phase Clinical trials as member of POETIC. Additionally, I have participated in all levels of clinical trial development, conduct, and monitoring
(Data Safety Monitoring, Scientific Review, IRB membership).

I am currently the Chair of the Data Safety Monitoring Committee B for the Children’s Oncology Group that monitors all Phase1, 2 and pilot studies being pursued in in COG and in the Developmental Therapeutics Consortium of COG.